xRead - September 2022

Wise et al.

Page 239

1152. Vredegoor DW, Willemse T, Chapman MD, Heederik DJ, Krop EJ. Can f 1 levels in hair and homes of different dog breeds: lack of evidence to describe any dog breed as hypoallergenic. J Allergy Clin Immunol. 2012;130:904–909 e907. [PubMed: 22728082] 1153. Arshad SH. Environmental control for secondary prevention of asthma. Clin Exp Allergy. 2010;40:2–4. [PubMed: 20205691] 1154. National Asthma Education Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol. 2007;120:S94–S138. [PubMed: 17983880] 1155. Kalyoncu A A new approach to an old problem: controversial issues in seasonal rhinoconjunctivitis. J Allergy Ther. 2014;5:164–166. 1156. D’Amato G, Cecchi L, Bonini S, et al. Allergenic pollen and pollen allergy in Europe. Allergy. 2007;62:976–990. [PubMed: 17521313] 1157. Bastl K, Berger M, Bergmann KC, Kmenta M, Berger U. The medical and scientific responsibility of pollen information services. Wien Klin Wochenschr. 2017;129:70–74. [PubMed: 27761736] 1158. Kiotseridis H, Cilio CM, Bjermer L, Tunsater A, Jacobsson H, Dahl A. Grass pollen allergy in children and adolescents-symptoms, health related quality of life and the value of pollen prognosis. Clin Transl Allergy. 2013;3:19. [PubMed: 23799882] 1159. Ferguson BJ. Environmental controls of allergies. Otolaryngol Clin North Am. 2008;41:411– 417, viii-ix. [PubMed: 18328378] 1160. Reisacher WR. Allergy treatment: environmental control strategies. Otolaryngol Clin North Am. 2011;44:711–725, x. [PubMed: 21621056] 1161. Comert S, Karakaya G, Kalyoncu AF. Wraparound eyeglasses improve symptoms and quality of life in patients with seasonal allergic rhinoconjunctivitis. Int Forum Allergy Rhinol. 2016;6:722– 730. [PubMed: 26919554] 1162. Kenney P, Hilberg O, Pedersen H, Nielsen OB, Sigsgaard T. Nasal filters for the treatment of allergic rhinitis: a randomized, double-blind, placebo-controlled crossover clinical trial. J Allergy Clin Immunol. 2014;133:1477–1480.e13. [PubMed: 24589343] 1163. Kenney P, Hilberg O, Laursen AC, Peel RG, Sigsgaard T. Preventive effect of nasal filters on allergic rhinitis: a randomized, double-blind, placebo-controlled crossover park study. J Allergy Clin Immunol. 2015;136:1566–1572.e5. [PubMed: 26141263] 1164. Ellenbecker MJ. Engineering controls as an intervention to reduce worker exposure. Am J Ind Med. 1996;29:303–307. [PubMed: 8728129] 1165. Castano R, Trudeau C, Castellanos L, Malo JL. Prospective outcome assessment of occupational rhinitis after removal from exposure. J Occup Environ Med. 2013;55:579–585. [PubMed: 23618893] 1166. Casale TB, Blaiss MS, Gelfand E, et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol. 2003;111:S835–S842. [PubMed: 12743547] 1167. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126:466–476. [PubMed: 20816182] 1168. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA. 1993;269:1532–1536. [PubMed: 8445816] 1169. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89:1363–1372. [PubMed: 14594906] 1170. Bousquet J, Bindslev-Jensen C, Canonica GW, et al. The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine. Allergy. 2004;59(Suppl 77):4–16. 1171. Compalati E, Canonica GW. Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis. Curr Med Res Opin. 2013;29:1539–1551. [PubMed: 23826741] 1172. Blaiss MS. Cost-effectiveness of H1-antihistamines. Clin Allergy Immunol. 2002;17:319–336. [PubMed: 12113222]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.